AHN Cancer Institute Becomes One of Nation’s First to Use Breakthrough Technology to Advance Radiation Therapy
Share Article
Allegheny Health Network (AHN) Cancer Institute is one of just six U.S. health systems, and the first in western Pennsylvania, to begin treating cancer patients with the Elekta Unity MR-Linac, an innovative first-of-its-kind technology that combines diagnostic quality Magnetic Resonance Imaging (MRI) and linear accelerator radiotherapy in one interactive machine to more accurately and safely eradicate malignant tumors.
The Elekta Unity MR-Linac at AHN Allegheny General Hospital
“The MR-Linac will enable us to deliver higher doses of radiation to cancerous tumors more accurately and safely.and is also uniquely suited to the treatment of tumors that cannot be treated with standard technologies. Tom Colonias, MD, Director of Thoracic Malignancies, AHN Cancer Institute
Registration for the 23rd Annual V Foundation Wine Celebration weekend has begun.
This year s Wine Celebration, raising money for cancer research, will best be experienced as a three-day series of events from Thursday, Aug. 5 through Saturday, Aug. 7.
The inaugural Dinner with the Docs event will be on Thursday Aug. 5, featuring members of Scientific Advisory Committee, hosted by Beth Nickel at Far Niente Winery. Following that evening, guests will be treated to a reception and private concert at Alpha Omega Winery with hosts Robin and Michelle Baggett.Â
The ever-popular Rock the V Party on Friday, Aug. 6, will unite some of the Vintner Grant Honorees in a Vintner BBQ Showdown, with special guests and other V friends who will help cheer along the festivities.
Dramatic Rise in Use of Drugs for Opioid-Induced Constipation medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Canva; Everyday Health
The annual meeting of the American Association for Cancer Research (AACR) is one of the largest cancer research meetings of its kind, bringing together a range of researchers, from those who spend their time in the lab to those who focus on patients in the clinic. The meeting atmosphere is electric even when it’s virtual. Here are five key studies that stood out during the first week of the virtual AACR meeting, held April 10–15, 2021.
Lymphoma Progression Cut in Half When Rituxan Is Paired With Aliqopa
What’s new Patients with relapsed indolent non-Hodgkin lymphoma saw a 48 percent reduced risk of progression (time without the disease advancing or death) when the targeted therapy Aliqopa (copanlisib) was used in combination with Rituxan (rituximab) versus Rituxan alone. Rituxan alone is the current standard therapy for relapses. The results, which come from a phase 3 trial known as CHRONOS-3, were announced at the AACR meeting and simultaneously p
Allegheny Health Network Offers T-VEC Virus-Based Treatment for Advanced Melanoma
Share Article
Pittsburgh-based Allegheny Health Network is offering patients with advanced melanoma treatment with an oncolytic (cancer-killing) virus called Imlygic or T-VEC. It is injected directly into the tumor, where it works by replicating inside the cancer cells.
AHN surgical oncologist Howard Edington, MD, talks with patient Paul Kirsch prior to treatment with T-VEC
“Unlike other therapies for advanced melanoma, T-VEC is usually well tolerated and is suitable for many patients, including the elderly. It also has a “bystander effect,” killing nearby tiny lesions in addition to the primary tumor.” - Howard Edington, MD, AHN surgical oncologist